Overview

GSK1550188 A 52 Week Study of Belimumab Versus Placebo in the Treatment of Subjects With Systemic Lupus Erythematosus (SLE) Located in Northeast Asia

Status:
Completed

Trial end date:
2018-09-21

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy and safety of belimumab in addition to standard therapy compared to placebo in subjects in Northeast Asia with systemic lupus erythematosus (SLE) over a 52 week period.

Phase:

Phase 3

Details

Lead Sponsor:

GlaxoSmithKline

Collaborator:

Human Genome Sciences Inc.

Treatments:

Belimumab